CN110234350A - 针对包括动脉粥样硬化性心血管疾病的动脉粥样硬化的组合疗法 - Google Patents

针对包括动脉粥样硬化性心血管疾病的动脉粥样硬化的组合疗法 Download PDF

Info

Publication number
CN110234350A
CN110234350A CN201780083280.9A CN201780083280A CN110234350A CN 110234350 A CN110234350 A CN 110234350A CN 201780083280 A CN201780083280 A CN 201780083280A CN 110234350 A CN110234350 A CN 110234350A
Authority
CN
China
Prior art keywords
subject
therapy
ldl
pcsk9
risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780083280.9A
Other languages
English (en)
Chinese (zh)
Inventor
R.M.索马拉特内
R.A.D.斯科特
S.瓦泽曼
N.霍纳普尔
S.尼科尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60484496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN110234350(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CN110234350A publication Critical patent/CN110234350A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201780083280.9A 2016-11-14 2017-11-13 针对包括动脉粥样硬化性心血管疾病的动脉粥样硬化的组合疗法 Pending CN110234350A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662421685P 2016-11-14 2016-11-14
US62/421685 2016-11-14
US201762471874P 2017-03-15 2017-03-15
US62/471874 2017-03-15
US201762515117P 2017-06-05 2017-06-05
US62/515117 2017-06-05
US201762581244P 2017-11-03 2017-11-03
US62/581244 2017-11-03
US201762584600P 2017-11-10 2017-11-10
US62/584600 2017-11-10
PCT/US2017/061346 WO2018089912A2 (en) 2016-11-14 2017-11-13 Combined therapies for atherosclerosis, including atherosclerotic cardiovascular disease

Publications (1)

Publication Number Publication Date
CN110234350A true CN110234350A (zh) 2019-09-13

Family

ID=60484496

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780083280.9A Pending CN110234350A (zh) 2016-11-14 2017-11-13 针对包括动脉粥样硬化性心血管疾病的动脉粥样硬化的组合疗法

Country Status (17)

Country Link
US (1) US20200368350A1 (enExample)
EP (1) EP3538149A2 (enExample)
JP (3) JP2019533715A (enExample)
KR (2) KR20240096648A (enExample)
CN (1) CN110234350A (enExample)
AU (2) AU2017356219A1 (enExample)
BR (1) BR112019009726A2 (enExample)
CA (1) CA3043700A1 (enExample)
CL (2) CL2019001304A1 (enExample)
CO (1) CO2019004814A2 (enExample)
IL (1) IL266579A (enExample)
JO (1) JOP20190112A1 (enExample)
MA (1) MA46758A (enExample)
MX (3) MX2019005627A (enExample)
TN (1) TN2019000156A1 (enExample)
WO (1) WO2018089912A2 (enExample)
ZA (1) ZA201902975B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112656792A (zh) * 2021-01-26 2021-04-16 首都医科大学宣武医院 洛美他派在制备用于治疗脑卒中引起的神经损伤药物中的新用途

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2954767A1 (en) * 2014-07-14 2016-01-21 Amgen Inc. Crystalline antibody formulations
JOP20190215A1 (ar) 2017-03-24 2019-09-19 Ionis Pharmaceuticals Inc مُعدّلات التعبير الوراثي عن pcsk9
AU2019315823A1 (en) * 2018-07-31 2021-04-01 Wen Tan New use of carbamate beta phenylethanolamine analogues for enhancing intracellular clearance of ldl cholesterol and for combining therapy with statins to enhance the efficacy and reduce adverse effects
WO2021012074A1 (en) * 2019-07-19 2021-01-28 Ebay Inc. Sample delta monitoring

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103841992A (zh) * 2011-05-10 2014-06-04 安姆根有限公司 治疗或预防胆固醇相关疾病的方法
WO2015142668A1 (en) * 2014-03-17 2015-09-24 Sanofi Methods for reducing cardiovascular risk

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG171676A1 (en) 2006-05-11 2011-06-29 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of the pcsk9 gene
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
WO2010078536A1 (en) * 2009-01-05 2010-07-08 Rxi Pharmaceuticals Corporation Inhibition of pcsk9 through rnai
EP2442792A4 (en) 2009-06-15 2015-12-23 Alnylam Pharmaceuticals Inc TESTING GENE PCSK9 LIPID-FORMULATED DSRNA
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
WO2012088313A1 (en) 2010-12-22 2012-06-28 Genentech, Inc. Anti-pcsk9 antibodies and methods of use
EP2673302A1 (en) 2011-02-11 2013-12-18 Irm Llc Pcsk9 antagonists
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
CN113156096A (zh) * 2015-01-09 2021-07-23 全球基因集团有限责任公司 用于诊断冠状动脉粥样硬化性疾病的基于血液的生物标志物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103841992A (zh) * 2011-05-10 2014-06-04 安姆根有限公司 治疗或预防胆固醇相关疾病的方法
WO2015142668A1 (en) * 2014-03-17 2015-09-24 Sanofi Methods for reducing cardiovascular risk

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
MARC S. SABATINE 等: "Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events"", 《 NEW ENGLAND JOURNAL OF MEDICINE 》 *
PURI RISHI 等: "Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV)", 《 AMERICAN HEART JOURNAL》 *
岑锦明等: "他汀类药物与冠状动脉粥样斑块进展和回缩关系的研究进展", 《岭南心血管病杂志》 *
张兴华等: "他汀类药物的临床应用进展", 《医学综述》 *
邹阳春: "强化降脂 逆转斑块 进一步改善心血管疾病预后", 《中国动脉硬化杂志》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112656792A (zh) * 2021-01-26 2021-04-16 首都医科大学宣武医院 洛美他派在制备用于治疗脑卒中引起的神经损伤药物中的新用途

Also Published As

Publication number Publication date
TN2019000156A1 (en) 2020-10-05
EP3538149A2 (en) 2019-09-18
JP2023071715A (ja) 2023-05-23
MX2025002106A (es) 2025-04-02
IL266579A (en) 2019-07-31
KR20190085963A (ko) 2019-07-19
CA3043700A1 (en) 2018-05-17
MX2024000805A (es) 2024-02-06
CL2019001304A1 (es) 2019-09-23
JOP20190112A1 (ar) 2019-05-14
CL2020002993A1 (es) 2021-05-14
ZA201902975B (en) 2020-01-29
KR20240096648A (ko) 2024-06-26
MX2019005627A (es) 2019-10-14
US20200368350A1 (en) 2020-11-26
JP2019533715A (ja) 2019-11-21
CO2019004814A2 (es) 2019-07-31
AU2024278180A1 (en) 2025-01-09
WO2018089912A2 (en) 2018-05-17
BR112019009726A2 (pt) 2019-08-13
MA46758A (fr) 2019-09-18
AU2017356219A1 (en) 2019-05-30
JP2025102770A (ja) 2025-07-08
WO2018089912A3 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
JP2024147744A (ja) 心血管リスクを低減させる方法
JP2025102770A (ja) アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法
Qureshi et al. A randomized, single ascending dose study of intravenous BIIB092 in healthy participants
JP2024109575A (ja) 対象の心血管イベントのリスクを低減する方法
US20190292273A1 (en) Methods for reducing cardiovascular risk
Ray et al. Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial
JP7744190B2 (ja) リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
Seed et al. Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure
Gailani et al. Targeting factor XI and factor XIa to prevent thrombosis
JP2021193124A (ja) Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
JP2022554020A (ja) 心房細動および／または心房粗動を患う対象における心血管イベントのリスクを低減する方法
KR102269716B1 (ko) Il-31 안타고니스트를 유효 성분으로서 함유하는, 투석 소양증의 예방용 및/또는 치료용 의약 조성물
JP2007523837A (ja) Ｃ反応性タンパク質のレベルを低減するための方法
KR20210145295A (ko) Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
IL266292B2 (en) treatment regimens
EA049586B1 (ru) Средства комбинированной терапии атеросклероза, включая атеросклеротическое сердечно-сосудистое заболевание
NZ794398A (en) Combined Therapies For Atherosclerosis, Including Atherosclerotic Cardiovascular Disease
WO2025259719A1 (en) Method of administering an anti-soluble urokinase plasominogen activator receptor antibody for the treatment of kidney disease
TW202508591A (zh) 癌症治療
HK40114248A (en) Methods for reducing cardiovascular risk
JP2023530424A (ja) アテローム性動脈硬化性心血管疾患を治療するための医薬化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination